Keel Point LLC Invests $233,000 in IQVIA Holdings Inc. (NYSE:IQV)

Keel Point LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 1,009 shares of the medical research company’s stock, valued at approximately $233,000.

A number of other large investors have also recently bought and sold shares of IQV. HighTower Advisors LLC boosted its stake in shares of IQVIA by 2.4% during the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after acquiring an additional 118 shares during the last quarter. Prudential PLC acquired a new stake in shares of IQVIA during the 1st quarter worth about $741,000. Baird Financial Group Inc. grew its holdings in shares of IQVIA by 2.3% during the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after buying an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after buying an additional 144 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of IQVIA by 82.2% during the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after buying an additional 250 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 over the last quarter. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.8 %

Shares of IQV stock opened at $229.20 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm’s 50 day moving average price is $244.16 and its two-hundred day moving average price is $221.33. The stock has a market cap of $41.60 billion, a price-to-earnings ratio of 31.44, a price-to-earnings-growth ratio of 2.24 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same quarter in the previous year, the business posted $2.54 EPS. The business’s quarterly revenue was up 3.5% on a year-over-year basis. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. UBS Group lifted their target price on shares of IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Evercore ISI upped their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research note on Thursday, February 15th. BTIG Research started coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price on the stock. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, Barclays increased their price objective on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.